Imagine a future where disease is intercepted earlier, better therapies are developed faster, people don’t become patients and patients are returned to health. At Glympse Bio, we are working to turn this future into a reality. Take a glimpse into that future, where we are taking a glimpse inside the body.
In many of today’s most common and serious diseases few biomarkers (biological markers of disease) have been identified that can effectively and reliably detect disease or track response to treatment. At Glympse, we asked ourselves a simple question: why not directly query disease activity instead? From this simple question we have built a disruptive, non-invasive technology to directly query disease activity inside the body. We’re now on a journey with our platform to transform disease detection, predict treatment responders, measure treatment response, and track patients back to health.
We are pioneering the development of synthetic biomarkers – biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence – that are bioengineered to be perfectly tunable to any disease, absolutely specific, and offer earlier measures of response to disease and treatment.
Our synthetic biomarkers are administered to patients and tailor-made to query the activity of key biological targets such as proteases – a class of enzymes that drive critical disease pathways. Synthetic biomarkers exploit the human body’s own proteases and in vivo trafficking to create perfectly refined and trackable markers of disease which are accurate, sensitive, specific and detectable in a simple noninvasive urine test. It’s the new frontier of liquid biopsy.
We are building a comprehensive database of real-time biological activity in the human body that drives insights to validate drug-target engagement, determine responders and non-responders, and drive earlier and stronger outcomes for patients. At the earliest stages, we can gain a glimpse into the stage and progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections.
At the core of our product engine is the integration of sophisticated machine learning and artificial intelligence to develop predictive algorithms targeting all clinically-relevant proteases involved in human biology and physiology. All trained by our unique approach that captures real-time biology inside the body – Glympse Inside™.
Our lead program is Non-Alcoholic Steatohepatitis (NASH), impacting 16 million people in the U.S. and 100 million worldwide. We are developing predictive biomarkers that allow us to noninvasively and accurately stage NASH with a liquid biopsy better than the current standard of invasive needle liver biopsy. The same liquid biopsy reliably measures response to therapy long before histopathology changes become visible.
Our next program is Oncology, impacting 14 million patients in the U.S. and 50 million worldwide. We are developing a synthetic biomarker-based liquid biopsy to directly track progression of specific cancers and response to treatment longitudinally, across a broad range of immunotherapies, targeted therapies, and other standards-of-care.
Our development pipeline features programs in Oncology and Infections with preclinical validation in 10+ additional diseases.
Our creative business model uniquely blends the best of a drug-device development and regulatory pathway, therapeutics go-to-market model, and a biology-rich data engine.
Sangeeta Bhatia leverages 'tiny technologies' of miniaturization to yield inventions with new applications in tissue regeneration, stem cell differentiation, medical diagnostics, predictive toxicology and drug delivery.
Founded in 2015, Glympse Bio is an MIT spin-out from the laboratory of renowned bioengineer, Dr. Sangeeta Bhatia. Glympse Bio is headquartered in Cambridge, MA.
Our team is committed to enhancing our understanding of human disease. Our goal is to better serve the needs of patients, clinicians, researchers, drug developers, and payors.
Our dedication to science, across all the disciplines we integrate, is fundamental. This focus drives us together to our most exciting discoveries. And we always deliver.
Disruption was never achieved by accepting the status quo. Every day we challenge what has been accepted as we aspire to deliver a better future.
We all act with courage as we strive to achieve our vision. We will not fear failure. We will celebrate and learn equally from our failures and successes.
Every role matters in our team. We collaborate to ensure our common objectives are achieved.
This is who we are. And we are unwavering in our commitment to act with the highest ethics and integrity, to each other and those we work with.
President & CEO
Caroline is a biopharmaceutical executive with over 20 years of experience successfully leading diverse, empowered and integrated teams. She has broad experience integrating science, business and the clinic to deliver differentiated value to patients. Most recently, she was Vice President, Head R&D Strategy and Planning at Bristol-Myers Squibb where she led portfolio strategy and operations. This included shaping BMS’s strategy and portfolio to deliver strong competitive positioning in immuno-oncology, immunoscience, fibrosis and cardiovascular, together with a new fit-for-purpose operating model. Her earlier career spanned leadership roles in commercial, market access, regulatory and drug development. An organic chemist by training, Caroline studied as an undergraduate and postgraduate at Imperial College, London.
Chief Scientific Officer
Wendy Winckler is an experienced scientific leader with a strong track record in oncology, genomics, bioinformatics, and translational research. Prior to joining Glympse, she was the Executive Director of Next Generation Diagnostics at the Novartis Institutes of Biomedical Research. There she built a team to develop and employ innovative genomic technologies and analytic methods to study biomarkers of response and resistance in oncology clinical trials. Previously, Wendy was the Director of the Genetic Analysis Platform at the Broad Institute of MIT and Harvard and co-principal investigator of the NIH Genotype-Tissue Expression (GTEx) program. Wendy studied genetics at UCLA and Harvard.
Chief Development Officer
Eric is a life science executive with 20 years of strategic and operational experience across both scientific and business functions within early-stage companies. He specializes in advancing innovative and cutting-edge technology platforms from concept to clinic. Eric joined Glympse Bio as its first full-time employee in 2016 and was responsible for building the R&D team and launching operations. Previously, he was a Program Executive at Epirus Biopharmaceuticals where he led multiple biosimilar programs as well as managing key international alliances. Prior to that, Eric was General Manager and Head of Operations at Acusphere, where he was responsible for R&D, regulatory affairs, manufacturing, business development, and intellectual property. Eric has a B.S. in Biomedical Engineering from Brown University, Master’s in Biomedical Engineering from Rutgers University, and Ph.D. in Medical Science from Brown University.
Chief Business Officer
Roopom is a life science business leader with 20 years experience covering strategy, financial advisory, operational and scientific roles. He has broad experience with startups to global Fortune 500 companies advising on corporate strategy, portfolio design, product development and commercialization, financing, partnerships and acquisitions. Most recently, he was President and CEO of RainDance Technologies (acquired by BioRad Labs) and led the company to become a pioneer in Liquid Biopsy for detecting cancer from a blood test. Previously, Roopom led teams at McKinsey, Leerink and Goldman Sachs where he completed 80+ healthcare transactions raising over $10Bn in capital financings, 30+ IPOs, and 20+ M&A transactions. His earlier career spanned scientific cancer research at the Dana Farber Cancer Institute and Human Genome Project. A biochemist and economist by training, Roopom has a graduate degree from Harvard and two undergrad degrees from MIT where he was elected a Howard Hughes Medical Institute Scholar.
Vice President, Finance
Martha is a senior financial professional with extensive experience designing and building financial planning and reporting solutions. Experience in both public and private companies in the Biotechnology, High Tech and Software industries. Proven ability to build finance teams, implement financial planning, forecasting and budgeting processes and systems, providing accurate and insightful analysis to senior level executives and investors and lead teams through M&A due diligence and post-acquisition integration. Most recently she was Vice President at Neutron Therapeutics where she established the Finance function for the company. Martha has a undergraduate and masters in Business Administration from Northeastern University.
Chairman of the Board
Stan is an inventor/entrepreneur who serves on a number of healthcare and medical technology boards. He’s been founding CEO of four medical technology companies including Cytyc Corp (modern pap smear), Exact Sciences (non-invasive screening for colorectal cancer), Helicos (single molecule DNA sequencing) and SynapDx (early detection of autism).
Stan holds 36 patents, primarily in methods for early detection of cancer. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2014 for his work on the early detection of cancer.
Stan graduated from Cooper Union in New York City with a BS degree in electrical engineering.
Board Director
Francis is a physician-scientist with broad experience in pharmaceutical research, clinical development and executive management during a career spanning more than 30 years with BMS, Schering-Plough and Glaxo. Francis retired from BMS as Executive Vice President, Chief Scientific Officer and Head of R&D. Francis has led highly productive discovery organizations which produced a pipeline of innovative medicines from in-house and external programs, helping numerous patients prevail against serious disease, and laying the foundation for significant company growth. He holds medical degrees from Cambridge University, U.K. and is a fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He is a member of the board of directors of Novo Holdings A/S, Denmark and Rubius Therapeutics, and Vice Chair of the Board of Trustees of Montclair State University, NJ. He has published numerous articles and book chapters on topics of medical interest and organizational effectiveness.
Board Director
Theresia co-founded Aspect Ventures, a leading early-stage venture firm with a unique focus on bridging the funding gap between angels and the larger multi-stage VC platforms through collaboration and diversity. She led the firm’s early investments in Cato Networks, Deserve, Exabeam, ForeScout (FSCT), The Muse, Crew and ShieldX. Prior to launching Aspect, Theresia was a Managing General Partner at Accel where she championed many successful companies through IPOs or acquisitions including Imperva (IMPV), Trulia (TRLA), LearnVest (Northwestern Mutual), Jasper Design (CDNS) and Kosmix (WMT). Earlier, she worked at Release Software, Bain & Company and Silicon Graphics. Theresia holds an ScB in Engineering magna cum laude from Brown University (where she serves as Treasurer of Brown’s Corporation board) and an MBA from Stanford. Theresia has been honored seven times as a member of Forbes’ Midas List of top venture capitalists.
Board Director
Robert is one of 10 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member. Dr. Langer has written more than 1,400 articles. He also has over 1,300 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 350 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history (h-index 262 with over 275,000 citations according to Google Scholar). He has received over 220 major awards. He is one of four living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; the 2008 Millennium Prize, the world’s largest technology prize; the 2012 Priestley Medal, the highest award of the American Chemical Society; the 2013 Wolf Prize in Chemistry; the 2014 Breakthrough Prize in Life Sciences; and the 2014 Kyoto Prize.
Board Director
Amy is a highly respected leader in biotech and pharma. She joined Polaris Partners in 2014 and brings her commercial expertise to the startup biotech community. She is currently Partner of the LS Polaris Innovation Fund and is the active CEO and Co-Founder of Lyndra. She is also a Director of Quentis and Kallyope. Previously, Amy was General Counsel at Pfizer, President of Pfizer Nutrition, and President of Pfizer Consumer Healthcare. She has received numerous awards including Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Boards of Alnylam, Blue Buffalo, Ironwood, and the Whitehead Institute. She was Phi Beta Kappa at Wesleyan and earned her J.D. from Yale Law School.
Carolyn Bertozzi, Ph.D.
Bass Professor of Chemistry, Stanford
Charles S. Craik, Ph.D.
Professor of Pharmaceutical Chemistry, UCSF
Scott Friedman, M.D.
Chief, Division of Liver Diseases, Icahn School of Medicine, Mt. Sinai
Rohit Loomba, M.D., MHSc.
Director of Hepatology; Vice Chief, Division of Gastroenterology, UCSD
Arun Sanyal, M.D.
Professor, Division of Gastroenterology, Hepatology & Nutrition, VCU
Gyongzi Szabo, M.D., Ph.D., FAASLD
Chief Academic Officer, Beth Israel Deaconess Medical Center
We are a dynamic and high energy team that is committed to pushing scientific boundaries in pursuit of our goals. We are creative, agile, resilient, and always have the ‘courage to continue’. We work as a team, committed to each other’s success, in an environment where every team member is important.
If you fit the Glympse Bio profile, we would love to talk to you! We are actively building our team and welcome talented individuals who are looking to make a lasting impact.
Glympse Bio has a proven, flexible and customizable technology platform – powered by a highly scalable product engine – that can be deployed in multiple markets and applications. Best of all, our platform comes packaged in a favorable device regulatory pathway and drug reimbursement model.
We are excellent collaborators who consistently deliver for partners that share our vision and passion for changing the way treatments are developed, healthcare is delivered, and patients are diagnosed, treated, and monitored. Together, we can do this and enhance value for our partners and ourselves.
We are looking for distinctive people to join our fabulous team. And we are growing rapidly!
